Disciplined Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Disciplined Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21	Closed	-$1.82K	–	285
2023 Q2	$1.82K	Hold	21	–	–	﹤0.01%	702
2023 Q1	$2.04K	Sell	21 -4	-16%	-$415	﹤0.01%	651
2022 Q4	$2.59K	Buy	25 +1	+4%	+$94	﹤0.01%	537
2022 Q3	$2K	Buy	24 +5	+26%	+$445	﹤0.01%	583
2022 Q2	$2K	Buy	19 +2	+12%	+$159	﹤0.01%	610
2022 Q1	$1K	Buy	+17	New	+$1.42K	﹤0.01%	886

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Disciplined Investments's BMRN Position: Q3 2023 in Review

Disciplined Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 21 shares — an estimated $1.82K sold.

Disciplined Investments first reported a position in BMRN in Q1 2022 and held it in 6 quarters. The position peaked at $2.59K in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Disciplined Investments reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Disciplined Investments sold 21 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $1.82K.
Disciplined Investments first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Disciplined Investments's BioMarin Pharmaceuticals position peaked at $2.59K in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.